Quarterly report · Q2
9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥493m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥589m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥508m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥319m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥674m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥292m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.23 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥371m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥356m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥805m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥472m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥721m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥334m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥751m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ca | Prior1YearInstant | 208453000 | JPY |
| Other ca | CurrentQuarterInstant | 143400000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -23519000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -24254000 | JPY |
| Current assets | Prior1YearInstant | 7310885000 | JPY |
| Current assets | CurrentQuarterInstant | 7707909000 | JPY |
| Buildings and structures | Prior1YearInstant | 4442450000 | JPY |
| Buildings and structures | CurrentQuarterInstant | 4405071000 | JPY |
| Accumulated depreciation buildings and structures | Prior1YearInstant | -992174000 | JPY |
| Accumulated depreciation buildings and structures | CurrentQuarterInstant | -1048933000 | JPY |
| Buildings and structures net | Prior1YearInstant | 3450275000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 3356138000 | JPY |
| Machinery equipment and vehicles | Prior1YearInstant | 24659000 | JPY |
| Machinery equipment and vehicles | CurrentQuarterInstant | 24659000 | JPY |
| Accumulated depreciation machinery equipment and vehicles | Prior1YearInstant | -21776000 | JPY |
| Accumulated depreciation machinery equipment and vehicles | CurrentQuarterInstant | -22304000 | JPY |
| Machinery equipment and vehicles net | Prior1YearInstant | 2883000 | JPY |
| Machinery equipment and vehicles net | CurrentQuarterInstant | 2355000 | JPY |
| Tools furniture and fixtures | Prior1YearInstant | 2394117000 | JPY |
| Tools furniture and fixtures | CurrentQuarterInstant | 2398758000 | JPY |
| Accumulated depreciation tools furniture and fixtures | Prior1YearInstant | -1867410000 | JPY |
| Accumulated depreciation tools furniture and fixtures | CurrentQuarterInstant | -1906262000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant | 526706000 | JPY |
| Tools furniture and fixtures net | CurrentQuarterInstant | 492496000 | JPY |
| Land | Prior1YearInstant | 3429506000 | JPY |
| Land | CurrentQuarterInstant | 3376552000 | JPY |
| Lease assets ppe | Prior1YearInstant | 782266000 | JPY |
| Lease assets ppe | CurrentQuarterInstant | 782266000 | JPY |
| Accumulated depreciation lease assets ppe | Prior1YearInstant | -160606000 | JPY |
| Accumulated depreciation lease assets ppe | CurrentQuarterInstant | -218045000 | JPY |
| Lease assets net ppe | Prior1YearInstant | 621660000 | JPY |
| Lease assets net ppe | CurrentQuarterInstant | 564220000 | JPY |
| Construction in progress | Prior1YearInstant | 417978000 | JPY |
| Construction in progress | CurrentQuarterInstant | 445363000 | JPY |
| Property plant and equipment | Prior1YearInstant | 8449010000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 8237126000 | JPY |
| Other ia | Prior1YearInstant | 89958000 | JPY |
| Other ia | CurrentQuarterInstant | 98687000 | JPY |
| Intangible assets | Prior1YearInstant | 89958000 | JPY |
| Intangible assets | CurrentQuarterInstant | 98687000 | JPY |
| Investment securities | Prior1YearInstant | 149763000 | JPY |
| Investment securities | CurrentQuarterInstant | 181915000 | JPY |
| Long term loans receivable | Prior1YearInstant | － | JPY |
| Long term loans receivable | CurrentQuarterInstant | 528000 | JPY |
| Long term prepaid expenses | Prior1YearInstant | 4169000 | JPY |
| Long term prepaid expenses | CurrentQuarterInstant | 3665000 | JPY |
| Guarantee deposits ioa | Prior1YearInstant | 164486000 | JPY |
| Guarantee deposits ioa | CurrentQuarterInstant | 160973000 | JPY |
| Deferred tax assets | Prior1YearInstant | 146473000 | JPY |
| Deferred tax assets | CurrentQuarterInstant | 140605000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |